Forward Management’s Core Laboratories CLB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
Sell
-2,571
Closed -$298K 61
2018
Q3
$298K Sell
2,571
-438
-15% -$49.4K 0.05% 115
2018
Q2
$380K Buy
3,009
+83
+3% +$10.1K 0.06% 127
2018
Q1
$317K Buy
2,926
+35
+1% +$3.87K 0.05% 154
2017
Q4
$316K Sell
2,891
-86
-3% -$8.58K 0.04% 157
2017
Q3
$294K Sell
2,977
-592
-17% -$57.4K 0.03% 156
2017
Q2
$361K Buy
3,569
+215
+6% +$23.2K 0.03% 155
2017
Q1
$387K Buy
3,354
+139
+4% +$16.2K 0.03% 147
2016
Q4
$386K Sell
3,215
-2,815
-47% -$312K 0.03% 172
2016
Q3
$678K Sell
6,030
-201
-3% -$23.2K 0.05% 144
2016
Q2
$772K Sell
6,231
-100
-2% -$12.1K 0.06% 129
2016
Q1
$712K Sell
6,331
-419
-6% -$43.5K 0.06% 156
2015
Q4
$735K Buy
6,750
+963
+17% +$110K 0.06% 160
2015
Q3
$578K Sell
5,787
-2,933
-34% -$319K 0.05% 188
2015
Q2
$994K Buy
8,720
+5,060
+138% +$614K 0.06% 183
2015
Q1
$383K Buy
+3,660
New +$390K 0.02% 265

Other funds holding CLB

Forward Management's CLB Position: Q4 2018 in Review

Forward Management sold out of Core Laboratories (CLB) in Q4 2018, closing a stake of 2,571 shares — an estimated $298K sold.

Forward Management first reported a position in CLB in Q1 2015 and held it in 15 quarters. The position peaked at $994K in Q2 2015. 320 funds tracked by Wall St. Rank hold CLB as of Q4 2018.

  • Forward Management reported no remaining Core Laboratories position as of Q4 2018 after selling out during the quarter.
  • Forward Management sold 2,571 Core Laboratories shares in Q4 2018, an estimated $298K.
  • Forward Management first reported a position in Core Laboratories in Q1 2015 and held it in 15 quarters.
  • Forward Management's Core Laboratories position peaked at $994K in Q2 2015.
  • 320 funds tracked by Wall St. Rank held Core Laboratories as of Q4 2018.

Based on Forward Management's 13F filing for Q4 2018, filed 1 Feb 2019.